Atriva Therapeutics

Clinical stage biopharmaceutical company spearheading antiviral drug innovation. #pandemicpreparedness #COVID19 #influenza #zapnometinib

[Atriva Therapeutics @AtrivaTx]

Atriva is excited to announce today’s start of our Co-CEO Christian Pangratz.
After a transition phase he will succeed Dr. Rainer Lichtenberger as CEO and spearhead our management team to ready Atriva for later stage clinical development of #zapnometinib.
https://t.co/olLEqTIYq6

[Atriva Therapeutics @AtrivaTx]

We’d like to invite you to attend Atriva’s presentation at #BiotechShowcase on Jan. 10 at 4:00 pm, room Franciscan A. Looking forward to discuss our first-in-class host-targeting candidate to treat viral infections with high pandemic potential, such as #COVID-19 and #influenza.

[CHEManager @chemanager]

Das IZB #Innovation and #Startup Center for Biotechnology, eines der führenden Biotechnologiezentren in #Europa mit über 50 ansässigen #Biotech Start-ups, gab jetzt den Einzug des Tübinger Biotechunternehmens @AtrivaTx Therapeutics GmbH ins #IZB bekannt.
https://t.co/1L6GjLa5Un

[BioWorld @BioWorld]

@AtrivaTx taking host-targeted antiviral approach into basket study (free w/registration) https://t.co/QQ9ibZgoSG #biotech #pharma #COVID19

[Atriva Therapeutics @AtrivaTx]

We’re attending #ChinaBio - November 10 and November 11
Atriva Therapeutics’ management team will be available for virtual partnering via the partneringONE platform:
https://t.co/nai10EbVNz

[Atriva Therapeutics @AtrivaTx]

We’re excited to announce that successful life science manager, Christian Pangratz, will be Atriva’s #CEO effective Jan 15, 2023, succeeding Dr. Rainer Lichtenberger, co-founder & CEO of Atriva, who will retire as planned in 2023.

More: https://t.co/wDBXtoBLdT
#team #leadership

[Atriva Therapeutics @AtrivaTx]

We’re at #BioFuture from November 7 through November 9!
CEO Dr. Rainer Lichtenberger and non-executive director Michael Grissinger will present #Atriva’s technology and development programs and will be available for #partnering meetings.
https://t.co/m4dRFirrkk

[Atriva Therapeutics @AtrivaTx]

Meet us!
#BIOEurope Leipzig:24-26.10.22
#BioFuture NYC:7-9.11.22
#ChinaBio virtual:10-11.11.22
@LSXleaders London:14.11.22
@BioCentury’s Biopharma Summit SF, CA:14-16.11.22
#BARDA industry Day:15-16.11.22
#Jefferies2022 Healthcare Conf. London:14-17.11.22
https://t.co/y5QD2qCIbd

[Atriva Therapeutics @AtrivaTx]

Proudly presented our new data from Ph2a RESPIRE study today at #Sachs Conference.
#Atriva is looking forward to more inspiring discussions around #zapnometinib’s potential in fighting viral diseases with a high pandemic risk, such as influenza, #COVID-19, #RSV and #Hanta.

[Atriva Therapeutics @AtrivaTx]

Big step forward against viral diseases with pandemic potential: The results of our #Phase 2a RESPIRE study provide clear proof of concept for the clinical benefit of #Atriva’s lead compound #zapnometinib and a favorable safety profile.

More info: https://t.co/S6lgPaTort

[Atriva Therapeutics @AtrivaTx]

Let’s meet up!
Connect with @Atriva at #Sachs_BEF from Sept 21, 2022 in #Basel, Switzerland.
Learn about Atriva in our company presentation and be ready for partnering with our CEO Dr. Rainer Lichtenberger and CMO Dr. Stephan Stenglein, M.D.

More info: https://t.co/N91Dw2r5iM

[Atriva Therapeutics @AtrivaTx]

We celebrate that #pandemicprepareness now receives a boost via @IFPMA’s #BerlinDeclaration.
Atriva contributes to preparedness with #zapnometinib, a host-targeting antiviral, unlikely to develop resistances
More info: https://t.co/6EV9t606ve

[Atriva Therapeutics @AtrivaTx]

Which structures are necessary to improve preparedness for future health crises?

We are thrilled to share an interview with Dr. Lichtenberger (Atriva) and Dr. Riedemann (#InflaRx) on the importance of #pandemicpreparedness from @BiocomDe's #biotech yearbook 2022!
@beat_cov

[Atriva Therapeutics @AtrivaTx]

Read the full publication here: https://t.co/foCrxEUuLj

[Atriva Therapeutics @AtrivaTx]

We are delighted about this new scientific paper in Frontiers of Pharmacology!
The paper reports on pharmacodynamic and pharmacokinetic parameters of zapnometinib, thus further strengthening its scientific evidence
#pandemicpreparedness

[Atriva Therapeutics @AtrivaTx]

Atriva CEO Dr. Lichtenberger has published a guest article in Plattform Life Sciences 2nd issue “Finanzieren&Investieren”. Here he calls for #pandemicpreparedness to remain a central obligation for the German government.
Read more: https://t.co/rVRvLcjlLi
#biotech @BEAT_COV

[Atriva Therapeutics @AtrivaTx]

.@Handelsblatt voices concerns on emerging resistances of #Paxlovid. Pandemic preparedness requires the development of multiple therapeutic approaches – we should make this a priority!
Read more: https://t.co/8bLx9raCrl
#pandemicpreparedness #antiviraltherapy #COVID19

[Atriva Therapeutics @AtrivaTx]

A huge thank you for interesting discussions at #BioEquity in Milan!
“Round two” - digital #partnering - is right around the corner.
If you haven’t had the chance to #meetus in Milan, schedule a meeting via partneringONE for May 23 or May 24.
https://t.co/Ay10neSPKI

[Atriva Therapeutics @AtrivaTx]

#Boungiorno Milano!
#Atriva is presenting an exciting investment case relevant for #pandemicpreparedness at #BioEquity2022
Our CEO, Dr. Lichtenberger, is also looking forward to discussing how Atriva is spearheading current drug innovation against viral infections.
#zapnometinib

[Atriva Therapeutics @AtrivaTx]

#Boungiorno Milano!
#Atriva is presenting an exciting investment case relevant for #pandemicpreparedness at #BioEquity2022
Our CEO, Dr. Lichtenberger, is also looking forward to discussing how Atriva is spearheading current drug innovation against viral infections.
#zapnometinib

[Atriva Therapeutics @AtrivaTx]

We are thrilled that @PharmaPinkSheet featured Atriva, our lead-compound #zapnometinib and our clinical development plans in its #Coronavirus Notebook!

Enjoy the read: https://t.co/rj8XpcFpk7
#PinkSheet